FDA expands Imcivree indication for children aged two and above
Rhythm Pharmaceuticals announces FDA approval of Imcivree for children aged 2 and above, targeting syndromic or monogenic obesity, including Bardet-Biedl syndrome and POMC/PCSK1/LEPR deficiencies. Imcivree is the first precision medicine for the MC4R pathway, showing significant weight and hunger reduction in trials.
Highlighted Terms
Related News
FDA expands Imcivree indication for children aged two and above
Rhythm Pharmaceuticals announces FDA approval of Imcivree for children aged 2 and above, targeting syndromic or monogenic obesity, including Bardet-Biedl syndrome and POMC/PCSK1/LEPR deficiencies. Imcivree is the first precision medicine for the MC4R pathway, showing significant weight and hunger reduction in trials.